{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T03:59:31Z","timestamp":1794801571908,"version":"4.9.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T00:00:00Z","timestamp":1611014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T00:00:00Z","timestamp":1611014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1038\/s41409-020-01201-w","type":"journal-article","created":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T09:02:16Z","timestamp":1611046936000},"page":"1426-1432","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Hematopoietic cell transplant in pediatric acute myeloid leukemia after similar upfront therapy; a comparison of conditioning regimens"],"prefix":"10.1038","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4283-5503","authenticated-orcid":false,"given":"A. B.","family":"Versluys","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2232-6952","authenticated-orcid":false,"given":"J. J.","family":"Boelens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0073-9660","authenticated-orcid":false,"given":"C.","family":"Pronk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lankester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8446-0220","authenticated-orcid":false,"given":"V.","family":"Bordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5848-4501","authenticated-orcid":false,"given":"J.","family":"Buechner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ifversen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2817-3299","authenticated-orcid":false,"given":"N.","family":"Jackmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9871-0961","authenticated-orcid":false,"given":"M.","family":"Sundin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Vettenranta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Abrahamsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Mellgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,19]]},"reference":[{"key":"1201_CR1","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.bbmt.2010.09.022","volume":"17","author":"BS Andersson","year":"2011","unstructured":"Andersson BS, Valdez BC, de Lima M, Wang X, Thall PF, Worth LL, et al. Clofarabine +\/- fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. Biol Blood Marrow Transplant. 2011;17:893\u2013900.","journal-title":"Biol Blood Marrow Transplant."},{"key":"1201_CR2","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1016\/j.bbmt.2016.06.023","volume":"22","author":"G Alatrash","year":"2016","unstructured":"Alatrash G, Thall PF, Valdez BC, Fox PS, Ning J, Garber HR, et al. Long-term outcomes after treatment with clofarabine +\/- fludarabine with once-daily intravenous busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant. 2016;22:1792\u2013800.","journal-title":"Biol Blood Marrow Transplant."},{"key":"1201_CR3","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.critrevonc.2014.10.009","volume":"93","author":"C Fozza","year":"2015","unstructured":"Fozza C. The role of Clofarabine in the treatment of adults with acute myeloid leukemia. Crit Rev Oncol Hematol. 2015;93:237\u201345.","journal-title":"Crit Rev Oncol Hematol."},{"key":"1201_CR4","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1080\/08880018.2017.1360970","volume":"34","author":"Y Messinger","year":"2017","unstructured":"Messinger Y, Boklan J, Goldberg J, DuBois SG, Oesterheld J, Abla O, et al. Combination of clofarabine, cyclophosphamide, and etoposide for relapsed or refractory childhood and adolescent acute myeloid leukemia. Pediatr Hematol Oncol. 2017;34:187\u201398.","journal-title":"Pediatr Hematol Oncol."},{"key":"1201_CR5","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.3324\/haematol.2017.187153","volume":"103","author":"NKA van Eijkelenburg","year":"2018","unstructured":"van Eijkelenburg NKA, Rasche M, Ghazaly E, Dworzak MN, Klingebiel T, Rossig C, et al. Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed\/refractory acute myeloid leukemia: a phase IB study. Haematologica. 2018;103:1484\u201392.","journal-title":"Haematologica."},{"key":"1201_CR6","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1080\/10428194.2017.1319051","volume":"58","author":"B Buttner","year":"2017","unstructured":"Buttner B, Knoth H, Kramer M, Oertel R, Seeling A, Sockel K, et al. Impact of pharmacokinetics on the toxicity and efficacy of clofarabine in patients with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma. 2017;58:2865\u201374.","journal-title":"Leuk Lymphoma."},{"key":"1201_CR7","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1182\/blood-2003-06-2122","volume":"103","author":"S Jeha","year":"2004","unstructured":"Jeha S, Gandhi V, Chan KW, McDonald L, Ramirez I, Madden R, et al. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood. 2004;103:784\u20139.","journal-title":"Blood."},{"key":"1201_CR8","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1111\/bjh.14720","volume":"178","author":"L Karlsson","year":"2017","unstructured":"Karlsson L, Forestier E, Hasle H, Jahnukainen K, Jonsson OG, Lausen B, et al. Outcome after intensive reinduction therapy and allogeneic stem cell transplant in paediatric relapsed acute myeloid leukaemia. Br J Haematol. 2017;178:592\u2013602.","journal-title":"Br J Haematol."},{"key":"1201_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/bjh.12900","volume":"166","author":"H Hasle","year":"2014","unstructured":"Hasle H. A critical review of which children with acute myeloid leukaemia need stem cell procedures. Br J Haematol. 2014;166:23\u201333.","journal-title":"Br J Haematol."},{"key":"1201_CR10","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1200\/JCO.1991.9.10.1880","volume":"9","author":"GL Phillips","year":"1991","unstructured":"Phillips GL, Shepherd JD, Barnett MJ, Lansdorp PM, Klingemann HG, Spinelli JJ, et al. Busulfan, cyclophosphamide, and melphalan conditioning for autologous bone marrow transplantation in hematologic malignancy. J Clin Oncol. 1991;9:1880\u20138.","journal-title":"J Clin Oncol."},{"key":"1201_CR11","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/leu.2010.297","volume":"25","author":"B Strahm","year":"2011","unstructured":"Strahm B, Nollke P, Zecca M, Korthof ET, Bierings M, Furlan I, et al. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOG-MDS 98 study. Leukemia. 2011;25:455\u201362.","journal-title":"Leukemia."},{"key":"1201_CR12","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41375-019-0584-8","volume":"34","author":"MG Sauer","year":"2020","unstructured":"Sauer MG, Lang PJ, Albert MH, Bader P, Creutzig U, Eyrich M, et al. Hematopoietic stem cell transplantation for children with acute myeloid leukemia-results of the AML SCT-BFM 2007 trial. Leukemia. 2020;34:613\u201324.","journal-title":"Leukemia."},{"key":"1201_CR13","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.bbmt.2016.11.022","volume":"23","author":"G Lucchini","year":"2017","unstructured":"Lucchini G, Labopin M, Beohou E, Dalissier A, Dalle JH, Cornish J, et al. Impact of conditioning regimen on outcomes for children with acute myeloid leukemia undergoing transplantation in first complete remission. An analysis on behalf of the Pediatric Disease Working Party of the European Group for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2017;23:467\u201374.","journal-title":"Biol Blood Marrow Transplant."},{"key":"1201_CR14","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1200\/JCO.1995.13.7.1786","volume":"13","author":"BL Samuels","year":"1995","unstructured":"Samuels BL, Bitran JD. High-dose intravenous melphalan: a review. J Clin Oncol. 1995;13:1786\u201399.","journal-title":"J Clin Oncol."},{"key":"1201_CR15","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.bbmt.2012.08.011","volume":"19","author":"UD Bayraktar","year":"2013","unstructured":"Bayraktar UD, Bashir Q, Qazilbash M, Champlin RE, Ciurea SO. Fifty years of melphalan use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013;19:344\u201356.","journal-title":"Biol Blood Marrow Transplant."},{"key":"1201_CR16","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/BF00686397","volume":"30","author":"M Hassan","year":"1992","unstructured":"Hassan M, Oberg G, Ericson K, Ehrsson H, Eriksson L, Ingvar M, et al. In vivo distribution of [11C]-busulfan in cynomolgus monkey and in the brain of a human patient. Cancer Chemother Pharmacol. 1992;30:81\u20135.","journal-title":"Cancer Chemother Pharmacol."},{"key":"1201_CR17","first-page":"113","volume":"4","author":"M Hassan","year":"1989","unstructured":"Hassan M, Ehrsson H, Smedmyr B, Totterman T, Wallin I, Oberg G, et al. Cerebrospinal fluid and plasma concentrations of busulfan during high-dose therapy. Bone Marrow Transplant. 1989;4:113\u20134.","journal-title":"Bone Marrow Transplant."},{"key":"1201_CR18","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1182\/blood.V80.9.2425.2425","volume":"80","author":"AM Yeager","year":"1992","unstructured":"Yeager AM, Wagner JE Jr, Graham ML, Jones RJ, Santos GW, Grochow LB. Optimization of busulfan dosage in children undergoing bone marrow transplantation: a pharmacokinetic study of dose escalation. Blood. 1992;80:2425\u20138.","journal-title":"Blood."},{"key":"1201_CR19","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/s41409-018-0281-7","volume":"54","author":"M Philippe","year":"2019","unstructured":"Philippe M, Neely M, Rushing T, Bertrand Y, Bleyzac N, Goutelle S. Maximal concentration of intravenous busulfan as a determinant of veno-occlusive disease: a pharmacokinetic-pharmacodynamic analysis in 293 hematopoietic stem cell transplanted children. Bone Marrow Transplant. 2019;54:448\u201357.","journal-title":"Bone Marrow Transplant."},{"key":"1201_CR20","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.bbmt.2013.11.027","volume":"20","author":"IH Bartelink","year":"2014","unstructured":"Bartelink IH, van Reij EM, Gerhardt CE, van Maarseveen EM, de Wildt A, Versluys B, et al. Fludarabine and exposure-targeted busulfan compares favorably with busulfan\/cyclophosphamide-based regimens in pediatric hematopoietic cell transplantation: maintaining efficacy with less toxicity. Biol Blood Marrow Transplant. 2014;20:345\u201353.","journal-title":"Biol Blood Marrow Transplant."},{"key":"1201_CR21","doi-asserted-by":"publisher","first-page":"e13158","DOI":"10.1111\/petr.13158","volume":"22","author":"A Zaucha-Prazmo","year":"2018","unstructured":"Zaucha-Prazmo A, Gozdzik J, Debski R, Drabko K, Sadurska E, Kowalczyk JR. Transplant-related mortality and survival in children with malignancies treated with allogeneic hematopoietic stem cell transplantation. A multicenter analysis. Pediatr Transplant. 2018;22:e13158.","journal-title":"Pediatr Transplant."},{"key":"1201_CR22","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s12185-010-0584-y","volume":"91","author":"Y Ishida","year":"2010","unstructured":"Ishida Y, Honda M, Ozono S, Okamura J, Asami K, Maeda N, et al. Late effects and quality of life of childhood cancer survivors: part 1. Impact of stem cell transplantation. Int J Hematol. 2010;91:865\u201376.","journal-title":"Int J Hematol."},{"key":"1201_CR23","doi-asserted-by":"publisher","first-page":"e182453","DOI":"10.1001\/jamaoncol.2018.2453","volume":"4","author":"AS Holmqvist","year":"2018","unstructured":"Holmqvist AS, Chen Y, Wu J, Battles K, Bhatia R, Francisco L, et al. Assessment of late mortality risk after allogeneic blood or marrow transplantation performed in childhood. JAMA Oncol. 2018;4:e182453.","journal-title":"JAMA Oncol."}],"updated-by":[{"DOI":"10.1038\/s41409-021-01257-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T00:00:00Z","timestamp":1615766400000}}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41409-020-01201-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-020-01201-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-020-01201-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:17:29Z","timestamp":1684617449000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-020-01201-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,19]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["1201"],"URL":"https:\/\/doi.org\/10.1038\/s41409-020-01201-w","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41409-021-01257-2","asserted-by":"object"}]},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,19]]},"assertion":[{"value":"10 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2021","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41409-021-01257-2","URL":"https:\/\/doi.org\/10.1038\/s41409-021-01257-2","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}